A look at the pharma giant's earnings forecast for the year ahead, with Jean-Pierre Garnier, GlaxoSmithKline CEO and CNBC's Mike Huckman

15

...d; Lonza profit beats estimates on shift toward drug ingredients; Analysis by Andrew Witty, GlaxoSmithKline CEO; Analysis by Gbola Amusa of UBS; Report and analysis by Ryan Chilcotte of Bloomberg ...

Europe's GlaxoSmithKline doubled its share buyback program to $25 billion on Wednesday, boosting its shares before the FDA meeting on Monday...

60

Analysis by Andrew Witty, GlaxoSmithKline CEO; Analysis by Gbola Amusa of UBS; Analysis by Jeremy Batstone-Carr of Charles Stanley

...outlook ... its possible strategy under chief executive officer-designate Andrew Witty, who will succeed CEO Jean-Pierre Garnier in May. GlaxoSmithKline is Europe's largest drugmaker. (Source: ...

...outlook for new products and second-quarter earnings reported today. A U.S. Food and Drug Administration committee meets on July 30 to review Avandia's safety after researchers said on May 21 that ...